ArticleOpen forum infectious diseases2026
The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytomegalovirus (CMV) remains the most common viral infection after hematopoietic stem cell transplantation (HSCT). The clinical significance of different CMV DNA forms remains unclear, particularly regarding CMV-specific immune reconstitution. Methods: A total of 76 HSCT recipients were enrolled. A quantitative DNase I-resistant CMV-DNA assay was performed to distinguish infectious from noninfectious CMV DNA. Based on DNase treatment results, patients were divided into 3 groups: (1) negative DNAemia (ND, n = 25): with no detectable CMV DNA; (2) DNase I-sensitive DNAemia (DSD, n = 26): with only DNase I-sensitive CMV DNA detected; (3) DNase I-resistant DNAemia (DRD, n = 25): with at least one episode of DNase I-resistant CMV DNAemia within 100 days posttransplant. CMV-specific T-cell responses were evaluated by multiparameter flow cytometry, and cytokine polyfunctionality was quantified using Combinatorial Polyfunctionality Analysis of Antigen-Specific T-cell Subsets analysis. Results: Early CMV reactivation was associated with stronger CD8 Conclusions: Cytomegalovirus-specific immune reconstitution appears delayed in DSD compared with DRD patients, potentially reflecting limited exposure to replication-competent virus. Assessment of CMV-specific T-cell polyfunctionality may help identify HSCT recipients at increased risk for late CMV reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.